NEW YORK – A multiplex molecular panel to detect pneumonia-causing pathogens has been shown to potentially benefit patient care, according to a handful of recent studies. In one study, the test, from BioMérieux subsidiary BioFire Diagnostics, was shown to have the potential to adjust antimicrobial therapy in approximately 70 percent of cases, sparing patients six days of unnecessary empiric treatment.
Additionally, the panel is finding a place in the COVID-19 diagnostic testing workflow in the UK.